Case Report
Early-Onset Neutropenia Induced by Rituximab in a Patient with Lupus Nephritis and Hemolytic Anemia
Table 1
Adult SLE patients presenting with early-onset neutropenia associated with rituximab therapy.
| | Author/year | Gender/age (years)/ethnicity | Active clinical manifestations | Prior immunosuppressive therapy | Concomitant immunosuppressive treatment | Number of weekly rituximab infusions/dose | Time to neutropenia after 1st dose of rituximab (days) |
| | Gottenberg et al./2005 [8] | F/30/NA | Pleuropericarditis | NA | None | 1/375 mg/m2 | 10 | | Gottenberg et al./2005 [8] | F/22/NA | Articular | Cyclophosphamide | Mycophenolate mofetil | 4/375 mg/m2 | 15 | | Enríquez et al./2007 [11] | F/48/Caucasian | Polyarthritis, nonnephrotic range proteinuria | Cyclophosphamide | None | 2/375 mg/m2 | 15 | | Current report/2014 | F/32/Hispanic | Oral ulcers, rash, hemolytic anemia, and nephrotic syndrome | Cyclophosphamide | Mycophenolate mofetil | 4/375 mg/m2 | 15 |
|
|
SLE: systemic lupus erythematosus; NA: not available.
|
